rethinkPeptides Search
Menu
Home / Research library
Study breakdown

BPC-157 Provides Long-Lasting Stomach Protection Against Chronic Alcohol Damage

RPEP-006912001Prkacin, I; Aralica, G; Perovic, D; Separovic, J; Gjurasin, M; Lovric-Bencic, M; Stancic-Rokotov, D; Ziger, T; Anic, T; Sikiric, P; Seiwerth, S; Staresinic, M; Mise, S; Rotkvic, I; Jagic, V; Rucman, R; Petek, M; Turkovic, B; Marovic, A; Sjekavica, I; Sebecic, B; Boban-Blagaic, A; Ivasovic, Z
Animal StudyPreliminary evidence
The takeaway

BPC-157, ranitidine, and propranolol all provided chronic cytoprotection against alcohol-induced gastric lesions in rats, with BPC-157 showing persistent benefit throughout the chronic alcohol exposure period.

Sustained chronic protection

BPC-157 didn't lose effectiveness during prolonged alcohol exposure — maintained gastroprotection throughout the chronic drinking period

What the researchers found

BPC-157 provided sustained chronic cytoprotection against alcohol-induced gastric lesions, with effectiveness maintained throughout prolonged alcohol exposure alongside liver protection documented in companion study.

Why it matters

Chronic drinkers need sustained stomach protection. BPC-157's persistent effectiveness during prolonged alcohol exposure is practically important for real-world alcohol-related gastropathy.

How the study worked

Animal study in rats with chronic alcohol administration (3.03 or 7.28 g/kg/day). BPC-157, ranitidine, and propranolol tested for prevention, attenuation, and reversal of chronic gastric lesions.

What this study cannot tell us

Rat model. Chronic alcohol doses are standardized; human drinking patterns vary. BPC-157 dosing optimization for chronic use not established.

How to read the evidence

Preliminary animal evidence with chronic exposure design providing clinically relevant duration data for gastroprotection.

When this study was published

Published in 2001. Companion to the portal hypertension study, together demonstrating BPC-157's dual stomach-liver protection.

The bigger picture

Combined with its liver protection (companion study), BPC-157 shows the ability to protect both stomach and liver during chronic alcohol exposure — addressing the two organs most damaged by alcoholism.

Questions still open

  • Can BPC-157 protect the entire GI tract during chronic alcohol use?
  • Does tolerance develop with very long-term BPC-157 use?
  • Is the gastroprotection mechanism different for chronic versus acute alcohol damage?

Common questions

Does BPC-157 still work after prolonged use?
Yes. Unlike some drugs that lose effectiveness over time, BPC-157 maintained its stomach protection throughout chronic alcohol exposure in rats — no evidence of tolerance.
Can it protect both stomach and liver?
Together with the companion study showing portal hypertension and liver protection, BPC-157 protects the two organs most damaged by chronic alcohol — stomach and liver — simultaneously.

Read the original research

Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats.

Journal of physiology, Paris, 95(1-6), 295-301

View on PubMed ↗

Citation

Prkacin, I; Aralica, G; Perovic, D; Separovic, J; Gjurasin, M; Lovric-Bencic, M; Stancic-Rokotov, D; Ziger, T; Anic, T; Sikiric, P; Seiwerth, S; Staresinic, M; Mise, S; Rotkvic, I; Jagic, V; Rucman, R; Petek, M; Turkovic, B; Marovic, A; Sjekavica, I; Sebecic, B; Boban-Blagaic, A; Ivasovic, Z. (2001). Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats.. Journal of physiology, Paris, 95(1-6), 295-301.